Pharma Developments: Depression-Cholesterol Link, Lilly’s Aderum Deal, and Cambrex Growth
The pharmaceutical industry rarely pauses. Whilst researchers uncover surprising metabolic links to mental health, corporate dealmakers restructure competitive landscapes, and manufacturers race to meet surging global drug demand. Three recent developments illuminate this sector’s relentless evolution. Emerging clinical research now firmly connects cholesterol imbalances to heightened depression risk, challenging traditional boundaries between metabolic and mental […]






